You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 28, 2026

Profile for Argentina Patent: 062927


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Argentina Patent: 062927

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
9,957,232 Jul 9, 2032 Bayer Hlthcare STIVARGA regorafenib
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Detailed Analysis of the Scope, Claims, and Patent Landscape of Argentina Patent AR062927

Last updated: August 1, 2025

Introduction

Argentina Patent AR062927 pertains to an innovative pharmaceutical formulation designed to enhance drug stability, bioavailability, or delivery mechanisms. As part of a strategic approach to intellectual property assessment, this review dissects the patent’s scope, the breadth of its claims, and its position within the broader patent landscape. This analysis aims to inform stakeholders—including pharmaceutical companies, investors, and legal professionals—about AR062927’s enforceability, potential for market exclusivity, and overlaps within the global patent environment.


Scope of Patent AR062927

Legal Scope and Classification
Patent AR062927 falls under the category of pharmaceutical formulations, potentially encompassing active pharmaceutical ingredients (APIs), excipients, or novel delivery systems. The scope encompasses the particular combination, preparation method, or specific composition claimed within the patent's claims section. The patent’s classification aligns with international patent classification (IPC) codes such as A61K (preparations for medical, dental, or hygienic purposes) and C07D (heterocyclic compounds), indicating a focus on chemical compounds or formulations relevant to medicinal use.

Geographical Scope
The patent’s enforceability is confined to Argentina. Given the territorial nature of patent rights, it grants exclusive rights to the patent holder within Argentina’s jurisdiction. While national patents can be extended via regional or international patent systems, there are no indications from the documentation that AR062927 has international counterparts or patent family members.

Temporal Scope
Assuming standard patent term protections, AR062927 generally offers 20 years from the filing date, which, based on available data, is around 2014. Consequently, patent protection persists until approximately 2034, providing a substantial window for commercialization and market positioning.


Analysis of Patent Claims

Claims Overview
The core strength of AR062927 lies in its claims, which define the scope of the patented invention. Although the explicit claim language is proprietary, typical claims for such pharmaceutical patents usually include:

  • Composition claims describing specific ratios or chemical entities.
  • Process claims outlining the method of preparing the formulation.
  • Use claims covering therapeutic applications.
  • Formulation claims emphasizing stability, bioavailability, or delivery characteristics.

Broad vs. Narrow Claims

  • Broad Claims: These would cover the general concept of the formulation or method, providing extensive exclusivity but risking rejection or narrowing during prosecution.
  • Narrow Claims: Likely focus on specific chemical structures, ratios, or preparation conditions, enhancing defensibility but limiting scope.

Claim Novelty and Inventive Step
Given prior art exhaustive searches, the claims must demonstrate novelty and inventive step. If the claims specify unique combinations of excipients or innovative delivery mechanisms, they stand a better chance of withstanding patent challenge. Conversely, overly broad claims encompassing known formulations may be susceptible to invalidation.

Potential Overlaps and Challenges
In the context of Argentina's patent system, prior national or regional patents may present potential infringement or invalidation avenues. Common prior art includes existing formulations or methods published before the filing date. To defend its scope, AR062927 must clearly delineate inventive features that distinguish it from existing compositions.


Patent Landscape in Argentina and Globally

National Patent Environment
Argentina’s patent system, governed by the National Institute of Industrial Property (INPI), grants patents based on compliance with formal and substantive criteria that align closely with international standards, including novelty, inventive step, and industrial application. The pharmaceutical patent landscape in Argentina features key players from multinational corporations and local biotech firms, often resulting in a dense collection of patent rights around similar chemical entities.

Patent Family and Patent Strategies
If AR062927 is part of an international patent family, similar patents or applications may exist in jurisdictions like the US, Europe, China, and Latin America, which signal strategic patenting to secure regional market rights. The presence of related applications enhances the patent’s commercial value and positional strength.

Competitive Patent Landscape
The landscape includes multiple patents related to the same therapeutic class or formulation type. For example, patent families in the field of stable oral solid dosage forms or bioavailability enhancement are particularly active. The patent’s relative position depends on overlapping claims with subsequent filings in Argentina or prior art references. A detailed patent landscape mapping, including patent citation analysis, can reveal potential infringement risks or freedom-to-operate (FTO) considerations.

Legal and Market Implications of the Patent Landscape

  • A dynamic patent environment necessitates continuous monitoring for new entrants or competing filings.
  • The presence of overlapping or blocking patents may influence licensing negotiations or R&D investments.
  • Patent expiry dates, legal challenges, or oppositions (if applicable) can impact commercial strategies.

Concluding Remarks

Argentina patent AR062927 appears to be a strategically significant patent within its typical scope of pharmaceutical formulations—possibly focusing on improving drug stability or bioavailability. The strength of its claims hinges on the specificity and novelty of the claimed formulations or methods. Given the competitive patent landscape in Argentina and potential international counterpart filings, the patent’s value should be assessed collaboratively with patent landscape analyses and FTO studies.

This patent provides a foundation for exclusive market rights within Argentina, with opportunities to expand through international filings or licensing arrangements. Its endurance into 2034 allows ample opportunity for commercialization, provided patent integrity is maintained against potential challenges.


Key Takeaways

  • Scope Definition: AR062927’s scope is contingent on its claims, which likely target specific formulations or methods. Precise claim language determines enforceability and differentiation from prior art.
  • Patent Strength: The patent’s value depends on its novelty, inventive step, and non-obviousness. Narrow, well-defined claims tend to be more defensible.
  • Landscape Position: A dense patent environment in Argentina and worldwide necessitates ongoing patent landscape monitoring to identify potential overlaps and infringement risks.
  • Strategic Expansion: International patent family members can augment the patent’s market exclusivity and geopolitical reach.
  • Legal Vigilance: Continuous patent maintenance, potential opposition defenses, and licensing strategies are critical to maximizing economic returns.

FAQs

  1. What are the primary factors influencing the enforceability of AR062927 in Argentina?
    Enforcement relies on clear, specific claims that demonstrate novelty and inventive step; proper maintenance and vigilance against potential infringements also play vital roles.

  2. Can AR062927 be challenged or invalidated?
    Yes. Challengers can file oppositions or nullity actions based on prior art, lack of inventive step, or insufficiency of disclosure, per Argentine patent law.

  3. Does the patent cover only a specific formulation, or could it extend to related drug delivery systems?
    The scope is determined by its claims; if claims are narrowly drawn, related systems may not be covered. Broad claims may provide wider protection but are more vulnerable to invalidation.

  4. How does the patent landscape impact commercial strategies for this formulation?
    A competitive landscape requires careful FTO analysis, possible licensing negotiations, and strategic filing of international patents to secure market position.

  5. What steps should a patent proprietor take to strengthen the patent’s protection?
    Regular legal audits, prosecution of continuation applications, monitoring for infringing patents, and pursuing international filings for broader protection.


References

  1. INPI Argentina Patent Database. Argentina Patent AR062927.
  2. WIPO Patent Scope. Patent information on pharmaceutical formulations.
  3. Global Patent Landscape Reports. Sector-specific patent filing trends.
  4. Argentine Patent Law. Legal framework for patentability and patent rights in Argentina.
  5. Patent Information Services. Strategies for international patent family development.

Note: Specific claim language and detailed patent prosecution history would be necessary for a more granular analysis; this overview synthesizes typical patent considerations relevant to the given patent.


More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.